# 醫療解決方案供應商 Q-Line Biotech 從基石投資者籌集了略超過 61 億盧比。

*biotech · news · 2026-05-21 · Outlook Business*

## Key points

- Q-Line Biotech 在其 NSE Emerge 首次公開募股前從基石投資者籌集了 61.09 億盧比。
- 基石股份以每股 343 盧比配發給包括 HDFC Bank 和 Abakkus Mutual Fund 在內的機構投資者。
- 整個首次公開募股為新發行的 625.3 萬股普通股，目標籌資 214.48 億盧比。
- Q-Line Biotech 截至 2025 年 12 月的九個月淨利潤增至 38.7 億盧比。

Q-Line Biotech, a healthcare solutions provider, on Wednesday said it has raised a little over Rs 61 crore from anchor investors, ahead of its maiden public offering on the NSE Emerge. The company has allotted over 17.81 lakh equity shares to Abakkus Mutual Fund, Carnelian Capital, Bharat Venture Opportunities Fund, 360 ONE, and HDFC Bank at an anchor investor price of Rs 343 per share, aggregating to Rs 61.09 crore, the company said in a statement. The fundraising comes a day ahead of the opening of its around Rs 214.48-crore share sale through the NSE Emerge. The issue will open for subscription on May 21 and conclude on May 25. The initial public offering (IPO) is entirely a fresh issue of 62.53 lakh equity shares with a face value of Rs 10 each. The company proposes to utilise net proceeds from the IPO to fund the working capital requirements, repayment of certain borrowings, and general corporate purposes. It is in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, supply of diagnostic equipment for different diagnostic healthcare needs. On the financial front, the company had posted a revenue of Rs 313.78 crore and profit after tax (PAT) of Rs 28.13 crore in FY25. During the nine-month period ended December 2025, Q-Line Biotech reported a revenue of Rs 232.42 crore and PAT of Rs 38.7 crore.

**Companies:** HDFC Bank, Q-Line Biotech
**Countries:** India

[Read the full story on Outlook Business](https://www.outlookbusiness.com/markets/q-line-biotech-mobilises-over-61-crore-from-anchor-investors-ipo-to-open-on-thursday)

---

Canonical: https://newsio.io/zh-TW/n/d8499303-2743-444b-b682-dd3f4798d335/q-line-biotech-61-17
Summarized by Newsio from Outlook Business. https://newsio.io/how-it-works